TREATMENT OF NON-SMALL CELL LUNG CANCER: THE NEXT STEP
- Authors: Borisova E.B1, Gutorov S.L1, Abramov M.E1
-
Affiliations:
- Issue: No 17 (2016)
- Pages: 25-29
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289321
- ID: 289321
Cite item
Open Access
Access granted
Abstract
The introduction of PD-1 inhibitors - nivolumab and pembrolizumab - into the second-line treatment of advanced non-small cell lung cancer (NSCLC) followed successful clinical trials of these drugs and was an important step in the development of treatment strategies in NSCLC. A new type of treatment showed a significant increase in objective response rate and overall survival and more favorable spectrum of complications compared to standard chemotherapy with docetaxel. The review discusses the features of assessment of the dynamics of disease manifestations during the treatment with inhibitors of the control points of the immune response, the specificity of drug toxicity, and issues of determining the PD-L1 expression requiring further development.
Keywords
Full Text
About the authors
E. B Borisova
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
S. L Gutorov
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
M. E Abramov
FSBI RORC n.a. N.N. Blokhin of RMH PhD, Senior Researcher at the Department of Chemotherapy and Combined Therapy of Malignant Tumors Moscow
References
- Herbst R.S., Gandara D.R., Hirsch F.R., Redman M.W., LeBlanc M., Mack P.C., Schwartz L.H., Vokes E., Ramalingam S.S., Bradley J.D., Sparks D., Zhou Y., Miwa C., Miller V.A., Yelensky R., Li Y., Allen J.D., Sigal E.V., Wholley D., Sigman C.C., Blumenthal G.M., Malik S., Kelloff G.J., Abrams J.S., Blanke C.D., Papadimitrakopoulou V.A. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin. Cancer. Res. 2015;21:1514-24.
- Тюляндин С.А. Ингибиторы контрольных точек иммунного ответа доказали свое преимущество перед доцетакселом в качестве второй линии лекарственного лечения больных немелкоклеточным раком легкого. http://www.rosoncoweb.ru/news/ oncology/2016/08/08-1/
- Brahmer J., Reckamp K.L., Baas P., Crinà L., Eberhardt W. E., Poddubskaya E., Antonia S., Pluzanski A., Vokes E.E., Holgado E., Waterhouse D., Ready N., Gainor J., Arén Frontera O., Havel L., Steins M., Garassino M.C., Aerts J.G., Domine M., Paz-Ares L., Reck M., Baudelet C., Harbison C.T., Lestini B., Spigel D.R. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med.
- Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Chow L.Q., Vokes E.E., Felip E., Holgado E., Barlesi F., Kohlhäufl M., Arrieta O., Burgio M.A., Fayette J., Lena H., Poddubskaya E., Gerber D.E., Gettinger S.N., Rudin C.M., Rizvi N., Crind L., Blumenschein G.R. Jr, Antonia S.J., Dorange C., Harbison C.T., Brahmer J.R., Graf Finckenstein F. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015;373:1627-39.
- Borghaei H., Brahmer J.R., Horn L., Ready N., Steins S., Felip E., Paz-Ares L.G., Arrieta O., Barlesi F., Antonia S.J., Fayette J., Rizvi N.A., Crino L., Reck M., Eberhardt W.E.E., Hellmann M.D., Desai K., Li A., Healey D.I., Spigel D.R. Nivolumab vs docetaxel in patients with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. J. Clin. Oncol. 2016;34 (Suppl.; Abstr. 9025).
- Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science. 2015; 348(6230):69-74.
- Herbst R.S., Baas P., Kim D.W., Felip E., Pérez-Gracia J.L., Han J.Y., Molina J., Kim J.H., Arvis C.D., Ahn M.J., Majem M., Fidler M.J., de Castro G. Jr, Garrido M., Lubiniecki G.M., Shentu Y., Im E., Dolled-Filhart M., Garon E.B. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027): 1540-50.
- McLaughlin J., Han G., Schalper K.A., Carvajal-Hausdorf D., Pelekanou V., Rehman J., Velcheti V., Herbst R., LoRusso P., Rimm D.L. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2016;2(1):46-54.
- Carbognin L., Pilotto S., Milella M., Vaccaro V., Brunelli M., Calià A., Cuppone F., Sperduti I., Giannarelli D., Chilosi M., Bronte V., Scarpa A., Bria E., Tortora G. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142.
- Kazandjian D., Suzman D.L., Blumenthal G., Mushti S., He K., Libeg M., Keegan P., Pazdur R. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist. 2016;21:634-42.
- Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1) Eur. J. Cancer. 2009;45:228-47.
- Reck M., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Lu H., Cuillerot J.M., Lynch T.J. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 2013;24(1):75-83.
- Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., LaoC.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., Ferrucci P.F., Hill A., Wagstaff J., Carlino M.S., Haanen J.B., Maio M., Marquez-Rodas I., McArthur G.A., Ascierto P.A., Long G.V., Callahan M.K., Postow M.A., Grossmann K., Sznol M., Dreno B., Bastholt L., Yang A., Rollin L.M., Horak C., Hodi F.S., Wolchok J.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015; 373:23-34.
Supplementary files
